Trial News & Events

NEALS Attends 2015 National ALS Advocacy Day and Public Policy Conference

The event which brought together people with ALS, representatives of nearly every major ALS organization, and advocates from across the country, provided a forum to share ALS stories, hear about the latest research opportunities and strategies, and urge Congress to make a difference in the fight against ALS.  The Northeast ALS Consortium (NEALS) was pleased to participate in The ALS Association’s 2015 National ALS Advocacy Day and Public Policy Conference, held in Washington, DC from May 10 through May 12. The event which brought together people with ALS, representatives of nearly every major ALS organization,…

NEALS Attends 2015 National ALS Advocacy Day and Public Policy Conference

The event which brought together people with ALS, representatives of nearly every major ALS organization, and advocates from across the country, provided a forum to share ALS stories, hear about the latest research opportunities and strategies, and urge Congress to make a difference in the fight against ALS. …

Progress coming in amyotrophic lateral sclerosis, but rigorous studies needed

The community of individuals living with amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, has endured many false hopes for promising therapies and is still waiting for the first disease-modifying drug. Nevertheless, "we have made huge progress in the last decade in ALS," Merit Cudkowicz, professor of neurology at Harvard Medical School and chief of the neurology service and director of the MDA ALS Clinic at Massachusetts General Hospital, told participants in an integrated neuroscience session on ALS at the American Academy of Neurology (AAN) 67th annual meeting. Read the entire article

NEALS Members Attend the American Academy of Neurology Annual Meeting in Washington, DC

The 67th American Academy of Neurology Annual Meeting took place in Washington, DC on April 22. This year, an overwhelming number of NEALS members were invited to participate; the membership gave multiple plenary talks, served as session chairs, participated in platform presentations, and presented over 25 abstract posters over the week-long program. If you weren't able to join in person for the event this year, all abstracts can be found

FDA ALS Statement

[FDA] call upon Genervon to release all the data from their recently completed trial in order to allow a more informed discussion of the trial findings among ALS stakeholders. Read the entire statement here.…

The ALS Association, Harvard Stem Cell Institute, and Massachusetts General Hospital Neurological Cl

The ALS Association, Harvard Stem Cell Institute, and Massachusetts General Hospital Neurological Clinical Research Institute today announced they are collaborating with GlaxoSmithKline (GSK) on a clinical trial to evaluate the potential of an anti-epileptic drug in ALS patients. The trial will evaluate the potential of the drug, Retigabine, which has a unique mechanism of action and can calm the excitability of nerve cells that are thought to cause seizures. Read the entire press release here.…

Ultra-high dose methylcobalamin (E0302) prolongs survival of ALS

Report of 7 years’ randomised double-blind, phase 3 clinical trial The present study demonstrated for the first time that ultra-high dose methylcobalamin can significantly prolong survival and retard progression in ALS if administered early. Read the full abstract here.…